J.J. Finkelstein, President & CEO of RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX; www.RegeneRx.com) today conducted an internet interview on CEOcast, one of the premier sources of original streaming broadcast interviews of Chief Executive Officers at public and private companies. In the interview, Mr. Finkelstein discussed the Company’s latest developments related to its platform technology and lead product, Thymosin beta 4 (Tß4), including research and development efforts, Tb4’s mechanism of action, clinical and regulatory developments, and partnership interests. Mr. Finkelstein also identified future milestones that may be of interest to current and potential investors.

To access the interview, navigate to www.ceocast.com, log-in to the site, and click on RegeneRx Biopharmaceuticals on the right side of the screen.

Tß4 is a naturally occurring 43 amino acid peptide and the major actin-sequestering molecule in mammalian cells. As such, it plays a vital role in the regeneration, remodeling, and healing of injured or damaged tissues. Tß4 is found in highest concentration in blood platelets, the first molecules to reach the site of a wound. It has also been shown to influence T-cell differentiation, decrease toxicity induced by endotoxin and chemotherapy, and down-regulate a number of key inflammatory cytokines and chemokines. Tß4 is the first actin-sequestering molecule to be tested for wound healing. It has a significantly different mechanism of action than other potential wound healing agents, including growth factors, and may be delivered topically, virtually eliminating toxicity while allowing easy accessibility for frequent treatment. Numerous recent papers have been published in major scientific journals describing the results of research on Tß4 conducted at the NIH and other institutions. Abstracts of these publications may be found at the company’s web site.

RegeneRx Biopharmaceuticals, Inc., Bethesda, MD, (www.RegeneRx.com) holds an exclusive worldwide license for Tß4 from NIH for wound healing and is developing it for the potential treatment of a variety of human diseases. The Company holds several patents related to the technology and has numerous patent applications pending. RegeneRx is initiating human clinical trials for chronic dermal wounds this quarter.

The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the regulatory approval process and the ongoing and prospective development and commercialization of T?b4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of clinical trials, product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.

Back To 2003 Press Release Archives